In a patient three days after total knee replacement who is on rivaroxaban (Xarelto) for VTE prophylaxis and now presents with mixed hematochezia and epigastric pain, without abdominal pain, nausea, vomiting, painful defecation, diarrhea, constipation, straining, or rectal lesions, what are the appropriate next diagnostic and management steps?

Immediate Management: Hold Rivaroxaban and Investigate for Upper GI Bleeding

This patient requires immediate cessation of rivaroxaban and urgent upper endoscopy to evaluate for upper gastrointestinal bleeding, given the combination of epigastric pain preceding defecation and blood mixed in stools on day 3 post-TKR. The clinical presentation strongly suggests an upper GI source rather than lower GI pathology.

Critical Clinical Assessment

Why This is Likely Upper GI Bleeding

The key clinical features pointing to upper GI bleeding include:

• Epigastric pain before defecation - suggests gastric or duodenal pathology
• Blood mixed in stools (not bright red blood per rectum) - consistent with melena or upper GI source
• Negative rectal exam - rules out anorectal pathology
• Day 3 post-TKR on rivaroxaban - peak timing for anticoagulant-related bleeding complications

Immediate Actions Required

1. Stop rivaroxaban immediately 1

   • Do not administer the next scheduled dose
   • Rivaroxaban has an 8-9 hour half-life; anticoagulant effect will diminish over 24-48 hours 2

2. Check hemoglobin/hematocrit urgently

   • Assess degree of blood loss
   • Establish baseline for monitoring

3. Obtain coagulation studies if available

   • PT/INR (will be prolonged with rivaroxaban)
   • Anti-Xa levels if available (though not necessary for management decisions)

4. Assess hemodynamic stability

   • Vital signs, orthostatic changes
   • Signs of significant blood loss

Diagnostic Workup

Upper Endoscopy (EGD) - First Priority

Schedule urgent upper endoscopy within 24 hours to evaluate for:

• Stress gastritis/ulceration - common in post-surgical patients
• Peptic ulcer disease - especially if patient on NSAIDs perioperatively
• Gastric erosions - related to surgical stress and anticoagulation
• Mallory-Weiss tear - though less likely without vomiting history

The combination of epigastric pain and rivaroxaban makes upper GI pathology the most probable source 3.

If Upper Endoscopy is Negative

Only then consider:

• Colonoscopy - though less likely given clinical presentation and recent normal colonoscopy
• CT angiography - if bleeding continues and source unclear
• Small bowel evaluation - capsule endoscopy or enteroscopy if other studies negative

Management of Rivaroxaban-Associated Bleeding

Supportive Care

• IV access and fluid resuscitation if hemodynamically unstable
• Type and cross-match blood products
• Transfuse if Hb <7-8 g/dL or symptomatic anemia

Reversal Considerations

For life-threatening bleeding only 2, 4:

• Four-factor prothrombin complex concentrate (PCC) - 50 units/kg IV
• Andexanet alfa - specific reversal agent for factor Xa inhibitors (if available)
• Activated charcoal - only if last dose within 2-3 hours 4

Do NOT use fresh frozen plasma or vitamin K - these are ineffective for rivaroxaban 2, 3.

For this patient with non-life-threatening bleeding, supportive care and drug discontinuation are sufficient 3, 4.

VTE Prophylaxis Management

Balancing Thrombosis vs. Bleeding Risk

Day 3 post-TKR represents high bleeding risk period 1. The guidelines clearly state:

• For high bleeding risk surgery (which TKR qualifies as), rivaroxaban should be resumed 48-72 hours (2-3 days) postoperatively 1
• This patient started rivaroxaban appropriately but has now developed bleeding

Resumption Strategy After Bleeding Control

Once bleeding is controlled and source treated:

1. Wait minimum 48-72 hours after hemostasis achieved before restarting any anticoagulation 1, 5

2. Consider alternative prophylaxis:

   • Mechanical prophylaxis - sequential compression devices, early mobilization
   • Low-dose LMWH (enoxaparin 40 mg daily or dalteparin 5000 IU daily) as bridge 5
   • Aspirin 325 mg daily - lower bleeding risk, though less effective for VTE prevention

3. If resuming rivaroxaban:

   • Start with reduced dose (10 mg daily) for 2-3 days 1
   • Monitor closely for recurrent bleeding
   • Consider PPI co-therapy if upper GI source confirmed

Common Pitfalls to Avoid

1. Don't assume lower GI source just because blood is in stool - epigastric pain is the key localizing symptom
2. Don't delay endoscopy waiting for "conservative management" - early diagnosis allows targeted therapy
3. Don't use reversal agents for non-life-threatening bleeding - supportive care is sufficient
4. Don't restart full-dose anticoagulation immediately after bleeding stops - use stepwise approach 1, 5
5. Don't forget mechanical prophylaxis while anticoagulation is held

Risk Stratification

This patient's VTE risk post-TKR remains elevated for several weeks, but bleeding risk currently outweighs thrombosis risk 1, 6. The incidence of symptomatic VTE after TKR with prophylaxis is approximately 1-2%, while major bleeding with rivaroxaban occurs in 0.3-1.5% of patients 7, 8, 9.

The priority is controlling the active bleeding, identifying and treating the source, then carefully reintroducing thromboprophylaxis with close monitoring.